More studies are needed to elucidate the signaling pathway involved in STAT3-induced HPS expression and the HPS-mediated EPA/ACC-1 lipogenic axis in KRAS-mutant pancreatic tumors, and our study hereby proposes that HPS is a promising therapeutic strategy for KRAS-mutated-driven pancreatic cancer. This evidence concerns the gene FGL1 and familial pancreatic carcinoma.